Free Trial
NASDAQ:INCY

Incyte (INCY) Stock Price, News & Analysis

Incyte logo
$70.34 +1.62 (+2.36%)
Closing price 04:00 PM Eastern
Extended Trading
$69.33 -1.01 (-1.44%)
As of 06:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Incyte Stock (NASDAQ:INCY)

Key Stats

Today's Range
$68.46
$70.62
50-Day Range
$58.98
$71.22
52-Week Range
$53.56
$83.95
Volume
1.39 million shs
Average Volume
1.96 million shs
Market Capitalization
$13.62 billion
P/E Ratio
219.82
Dividend Yield
N/A
Price Target
$74.53
Consensus Rating
Hold

Company Overview

Incyte Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
91st Percentile Overall Score

INCY MarketRank™: 

Incyte scored higher than 91% of companies evaluated by MarketBeat, and ranked 57th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Incyte has received a consensus rating of Hold. The company's average rating score is 2.22, and is based on 5 buy ratings, 12 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Incyte has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Incyte's stock forecast and price target.
  • Earnings Growth

    Earnings for Incyte are expected to grow by 34.57% in the coming year, from $4.86 to $6.54 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Incyte is 220.14, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.67.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Incyte is 220.14, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.18.

  • Price to Earnings Growth Ratio

    Incyte has a PEG Ratio of 0.57. PEG Ratios below 1 indicate that a company could be undervalued.

  • Price to Book Value per Share Ratio

    Incyte has a P/B Ratio of 3.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Incyte's valuation and earnings.
  • Percentage of Shares Shorted

    4.29% of the float of Incyte has been sold short.
  • Short Interest Ratio / Days to Cover

    Incyte has a short interest ratio ("days to cover") of 4.1.
  • Change versus previous month

    Short interest in Incyte has recently decreased by 2.85%, indicating that investor sentiment is improving.
  • Dividend Yield

    Incyte does not currently pay a dividend.

  • Dividend Growth

    Incyte does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.29% of the float of Incyte has been sold short.
  • Short Interest Ratio / Days to Cover

    Incyte has a short interest ratio ("days to cover") of 4.1.
  • Change versus previous month

    Short interest in Incyte has recently decreased by 2.85%, indicating that investor sentiment is improving.
  • News Sentiment

    Incyte has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 19 news articles for Incyte this week, compared to 17 articles on an average week.
  • Search Interest

    10 people have searched for INCY on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Incyte to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Incyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,371,385.00 in company stock.

  • Percentage Held by Insiders

    17.80% of the stock of Incyte is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    96.97% of the stock of Incyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Incyte's insider trading history.
Receive INCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter.

INCY Stock News Headlines

Incyte’s Q2 2025 Earnings: What to Expect
This Cold War “Accident” Could Unleash New $100 Trillion AI Boom
Obscure Metal More Valuable than Gold and Bitcoin… COMBINED? This strange "AI Metal" holds the key to the $100 trillion AI boom. Which is why Jeff Brown recently traveled to a location that has one of the highest concentrations of this metal in the world. And you won't believe what he uncovered.
Incyte to Report Second Quarter Financial Results
See More Headlines

INCY Stock Analysis - Frequently Asked Questions

Incyte's stock was trading at $69.07 at the start of the year. Since then, INCY stock has increased by 1.8% and is now trading at $70.3290.

Incyte Corporation (NASDAQ:INCY) issued its quarterly earnings data on Tuesday, April, 29th. The biopharmaceutical company reported $1.16 earnings per share for the quarter, topping analysts' consensus estimates of $1.01 by $0.15. Incyte's revenue for the quarter was up 19.5% compared to the same quarter last year.
Read the conference call transcript
.

Incyte's top institutional investors include Swedbank AB (0.32%), Wealth Enhancement Advisory Services LLC (0.04%), Czech National Bank (0.02%) and Pallas Capital Advisors LLC (0.02%). Insiders that own company stock include Maria E Pasquale, Steven H Stein, Barry P Flannelly, Vijay K Iyengar, Jonathan Elliott Dickinson, Sheila A Denton and Thomas Tray.
View institutional ownership trends
.

Shares of INCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Incyte investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and Southern First Bancshares (SFST).

Company Calendar

Last Earnings
4/29/2025
Today
7/10/2025
Next Earnings (Estimated)
7/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:INCY
CIK
879169
Employees
2,617
Year Founded
1991

Price Target and Rating

High Price Target
$107.00
Low Price Target
$52.00
Potential Upside/Downside
+8.5%
Consensus Rating
Hold
Rating Score (0-4)
2.22
Research Coverage
18 Analysts

Profitability

Trailing P/E Ratio
214.76
Forward P/E Ratio
14.14
P/E Growth
0.57
Net Income
$32.62 million
Pretax Margin
7.13%

Debt

Sales & Book Value

Annual Sales
$4.41 billion
Cash Flow
$0.56 per share
Price / Cash Flow
122.24
Book Value
$17.90 per share
Price / Book
3.84

Miscellaneous

Free Float
159,115,000
Market Cap
$13.30 billion
Optionable
Optionable
Beta
0.68

Social Links

The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:INCY) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners